Esther Zwiky, Tiana Borgers, Melissa Klug, Philine König, Konrad Schöniger, Janine Selle, Antonia Küttner, Luisa Brunner, Elisabeth J Leehr, Udo Dannlowski, Verena Enneking, Ronny Redlich
{"title":"Limbic gray matter increases in response to cognitive-behavioral therapy in major depressive disorder.","authors":"Esther Zwiky, Tiana Borgers, Melissa Klug, Philine König, Konrad Schöniger, Janine Selle, Antonia Küttner, Luisa Brunner, Elisabeth J Leehr, Udo Dannlowski, Verena Enneking, Ronny Redlich","doi":"10.1038/s41398-025-03545-7","DOIUrl":null,"url":null,"abstract":"<p><p>Major depressive disorder (MDD) is related to volumetric decreases in (cortico-)limbic brain regions. In contrast to pharmacological and electroconvulsive therapy, little is known about the brain structural effects of psychotherapy and potential links to symptom improvements. In a naturalistic longitudinal study using structural magnetic resonance tomography, gray matter volume (GMV) and clinical measures were assessed in 30 outpatients with MDD before and after 20 cognitive-behavioral therapy (CBT) sessions. Data from 30 healthy controls was acquired. Region-of-interest analyses revealed significant GMV increases within patients for the right anterior hippocampus and the bilateral amygdala, resulting in a significant group-by-time interaction for the left amygdala (p ≤ 0.022). Simultaneously, analyses revealed volumetric decreases in the right posterior hippocampus (p = 0.016). While there were no associations with overall symptom improvement, right amygdala volume increases were slightly associated with improvements in identifying feelings (r<sub>s</sub> = 0.321, p = 0.042). Together, findings show an impact of CBT not only on psychopathology but also on brain structure. The connection between CBT-related increased amygdala GMV and improved emotion identification emphasizes the role of improvements in emotional awareness.</p>","PeriodicalId":23278,"journal":{"name":"Translational Psychiatry","volume":"15 1","pages":"301"},"PeriodicalIF":6.2000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12381077/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41398-025-03545-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Major depressive disorder (MDD) is related to volumetric decreases in (cortico-)limbic brain regions. In contrast to pharmacological and electroconvulsive therapy, little is known about the brain structural effects of psychotherapy and potential links to symptom improvements. In a naturalistic longitudinal study using structural magnetic resonance tomography, gray matter volume (GMV) and clinical measures were assessed in 30 outpatients with MDD before and after 20 cognitive-behavioral therapy (CBT) sessions. Data from 30 healthy controls was acquired. Region-of-interest analyses revealed significant GMV increases within patients for the right anterior hippocampus and the bilateral amygdala, resulting in a significant group-by-time interaction for the left amygdala (p ≤ 0.022). Simultaneously, analyses revealed volumetric decreases in the right posterior hippocampus (p = 0.016). While there were no associations with overall symptom improvement, right amygdala volume increases were slightly associated with improvements in identifying feelings (rs = 0.321, p = 0.042). Together, findings show an impact of CBT not only on psychopathology but also on brain structure. The connection between CBT-related increased amygdala GMV and improved emotion identification emphasizes the role of improvements in emotional awareness.
期刊介绍:
Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod''s discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.